Patent Grant
9738932
The invention relates generally to the in vivo testing of the efficacy of a compound or composition, and particularly to the testing and biologically functionalizing of cox-2 inhibitory compounds (coxibs) by activity in vivo.
Use of cox-2 specific inhibitory compounds (coxibs) and some NSAIDs has been associated with an increased risk of cardiovascular events in human including deep venous thrombosis, myocardial infarction, stroke, and sudden death. The current hypothesis is that some of anti-inflammatory compounds inhibit PGI2 synthesis but not TxA synthesis, altering the homeostatic balance towards the pro-coagulative/pro-trombotic pathways. Fitzgerald G A. N Engl J Med. 351(17):1709-11 (Oct. 21, 2004). It has been reported that some of anti-inflammatory compounds, mainly cox-2 inhibitors, inhibit PGI2 synthesis only, resulting in altered homeostatic balance towards the pro-coagulative pathways which in rare cases might lead to the serious cardiovascular side effects in human. Furberg C D, Psaty B M, FitzGerald G A. Circulation. 111(3):249 (Jan. 25, 2005).
There continues to be a need in the art for additional information about the cardiovascular side effects of the use of cox-2 specific inhibitory compounds.
A 2-week analysis in cynomolgus monkeys (Macaca fascicularis) treated with the coxibs COX189 (Lumiracoxib®, Novartis), rofecoxib (Vioxx®, Merck), and celecoxib (Celebrex®, Pharmacia/Pfizer), and with the nonselective NSAID, diclofenac (Voltaren®, Novartis) showed that the Vioxx®—treated animals exhibit a specific mRNA expression pattern which shows the presence of an intravascular procoagulative/prothrombotic state particularly in venous vessels of a Vioxx®—treated monkey. The specific genomic pattern includes gene expression changes involved in blood and endothelial cell (EC) activation, interaction of blood cells with EC, activation of INFγ pathway, and release of pro-inflammatory cytokines and chemo-attractants. These data together with biochemical and histopathological findings indicate that Vioxx® induces or worsens the pro-coagulative/pro-thombotic changes, along with the activation of INFγ pathways triggered most probably by a endothelium tropic viral infection (e.g., cytomegalovirus (CMV)) and/or other vascular INFγ/TNF inducing situations (e.g., autoimmune vascular disorders).
The overall genomic findings show that Cox-2/PGE2 inhibition results in strong and uncontrolled induction of INFγ regulated chemo-attractants, adhesion molecules, and proinflammatory/pro-coagulative molecules which might lead to or increase the risk of cardiovascular adverse events. Histopathological results confirmed the genomic findings showing that the specific genomic pattern is an early signature of vasculitis and is observed only in the animal treated with Vioxx®.
Accordingly, the invention provides biomarkers (in the form of genomic information and serum or plasma proteins) for minimal and early vasculitis or other vasculopathies. In addition, the invention provides biomarkers for predicting potential Vioxx®-induced cardiovascular adverse effects.
Identification of biomarkers advantageously allows safe use of cox-2 inhibitory compounds in clinics and selection of cox-2 inhibitory follow-up compounds without cardiovascular toxicity. Indeed, the expression of several genes increased in the vessels of the Vioxx®-treated animal encode for secreted proteins, e.g., chemokine (CXC motif) ligand 10 (CXCL10) and other cytokines, which can be measured in peripheral samples such as blood or urine. Clinical screening of patients prior to, or during administration of Cox-2 inhibitory therapies should increase their safety profile.
Monitoring of early changes is predictive of cardiovascular adverse effects in patients treated with compounds exhibiting cox-2 inhibition or increasing the production of molecules induced by interferons, by virus infections, or autoimmune disorders resulting in pro-coagulative/prothrombotic/endothelium changes. These compounds include mainly cox-2 inhibitors, classical NSAIDs, other anti-inflammatory compounds and direct PGE2, cAMP and PKA inhibitors.
In one aspect of the invention, the data of the present invention identifies another pathway than the PGI2 synthesis pathway that may be one of the main triggering factors leading to the observed adverse cardiovascular events in human. Alteration in this pathway can be easily monitored in preclinical and clinical studies to avoid such cardiovascular side effects upon cox-2 and/or NSAIDs treatments. Biomarkers or the gene signature identified in this invention can also be used to monitor viral infection/INFγ pathway activation and some vasculopathies in diverse human diseases including several autoimmune and neurodegenerative disorders with or without anti-inflammatory and immunosuppressive treatments. Some of the biomarkers can be used for selection of compounds without potential cardiovascular side-effects.
Introduction and overview. The classical discovery process in the pharmaceutical industry is based on targets (enzymes, receptors, cellular assays, animal and disease models, etc.). Chemicals or biological products are tested, in a high-throughput mode, on a battery of pre-selected different targets. The weakness of the classical approach are the “artificially disconnected” in vitro target models compared to the tightly interconnected and interdependent relationship of the different targets in a whole organism and the fact that biological activity on all non selected targets is missed.
By contrast, the invention is a “non pre-conceived hypothesis” discovery process to rapidly identify and analyze the biological activity of new products in the whole organism, multi-organs and whole transcriptome. All physiological interactions between the different organs or tissues are present and any cellular pathway or any potential targets could potentially be analyzed in a non artificial system.
The data of the invention derived from this comparative multi-organ genomics analysis, coupled with extensive clinical, biochemical and histopathological data, identified a new pathway which may play the major role in the cardiovascular events observed in human treated with cox-2 inhibitors. The mRNA expression changes have been analyzed in several tissue samples from Macaca fascicularis following treatment with the Cox-2 specific inhibitors COX189 (Lumiracoxib®, Novartis), Rofecoxib (Vioxx®, Merck), and Celecoxib (Celebrex®, Pharmacia/Pfizer), and with the nonselective NSAID, Diclofenac (Voltaren®, Novartis).
Administration of compounds. A two-week oral-gavage treatment with the Cox-2 specific inhibitor COX189 (Lumiracoxib®, Novartis) in comparison with rofecoxib (Vioxx®, Merck), and celecoxib (Celebrex®, Pharmacia/Pfizer), and with the nonselective NSAID, diclofenac (Voltaren®, Novartis) was performed. All test items were administered to monkeys at doses higher than those used in patients to analyse mRNA expression changes in terms of mechanisms of drug actions and also potential cardiovascular toxic effects. The test items were administered daily at doses of 100 mg/kg/day, except Vioxx® which was administered at 50 mg/kg/day.
In one embodiment of the invention, the test animal is a vertebrate. In a particular embodiment, the vertebrate is a mammal. In a more particular embodiment, the mammal is a primate, such as a cynomolgus monkey (Macaca fascicularis). As used herein, the administration of an agent or drug to a subject includes self-administration and the administration by another.
In more particular embodiments, the “treatment group” of animals received a substance (test item, compound, drug) in a vehicle compound suitable for administration of the substance or the combination of substances, while the “control” (or “baseline”) group should receive the vehicle compound only. During the treatment period biological specimen such as tissue pieces (e.g. obtained by biopsy), or body fluids, such as blood, plasma, serum, urine, or saliva, can be sampled. At the end of the treatment time all animals of all groups can be sacrificed and biological specimen such as whole organs or pieces thereof can be sampled. All sampled specimen can be stored as known in the art for further analysis that include, but are not limited to, RT-PCR, Northern blotting, in-situ hybridization, gene expression profiling with microarrays.
In one embodiment, the invention begins with differentially expressed transcripts in different cardiovascular tissues and proteins in plasma between normal monkeys and cox-2 inhibitory compounds/drugs-treated monkeys with regard to the identification and validation of potential targets and the identification of biomarkers for cardiovascular side effects.
Gene expression profiles. After a period of time (e.g., four weeks) of compound/drug administration, the treated animals are necropsied. 120 tissues are dissected and rapidly snap-frozen for genomics analysis. Organ samples are isolated for histopathological examinations and for gene expression localizations, such as by in situ hybridization.
In more particular embodiments, the methods of detecting the level of expression of mRNA are well-known in the art and include, but are not limited to, reverse transcription PCR, real time quantitative PCR, Northern blotting and other hybridization methods. A particularly useful method for detecting the level of mRNA transcripts obtained from a plurality of genes involves hybridization of labelled mRNA to an ordered array of oligonucleotides. Such a method allows the level of transcription of a plurality of these genes to be determined simultaneously to generate gene expression profiles or patterns.
As used herein, a gene expression profile is diagnostic when the increased or decreased gene expression is an increase or decrease over the baseline gene expression following administration of a compound.
In one embodiment, the technique for detecting gene expression includes the use of a gene chip. The construction and use of gene chips are well known in the art. See, U.S. Pat. Nos. 5,202,231; 5,445,934; 5,525,464; 5,695,940; 5,744,305; 5,795,716 and 5,800,992. See also, Johnston, M. Curr Biol 8:R171-174 (1998); Iyer V R et al., Science 283:83-87 (1999) and Elias P, “New human genome ‘chip’ is a revolution in the offing” Los Angeles Daily News (Oct. 3, 2003).
Additional procedures that can be used in the methods of the invention are described in PCT/EP2004/012572, “USE OF ORGANIC COMPOUND”, filed Nov. 11, 2004, incorporated herein by reference).
Gene expression profiles have been generated using the Affymetrix microarray technology. (i) RNA extraction and purification: Briefly, total RNA was obtained by acid guanidinium thiocyanate-phenol-chloroform extraction (Trizol®, Invitrogen Life Technologies, San Diego, Calif.) from each frozen tissue section and the total RNA was then purified on an affinity resin (Rneasy®, Qiagen) according to the manufacturer's instructions. Total RNA was quantified by the absorbance at λ=260 nm (A260 nm) and the purity was estimated by the ratio A260 nm/A280 nm. Integrity of the RNA molecules was confirmed by non-denaturing agarose gel electrophoresis. RNA was stored at −80° C. until analysis. One part of each individual RNA sample was kept for the analysis of critical genes by means of Real-time PCR. (ii) GeneChip® experiment: All GeneChip® experiments were conducted in the Genomics Factory EU following recommendations by the manufacturer of the GeneChip® system (Affymetrix, Expression Analysis Technical Manual (Affymetrix, Santa Clara, Calif., 2005). Human U133A genome arrays were used for transcript expression analysis. Double stranded cDNA was synthesized with a starting amount of approximately 5 μg full-length total RNA using the Superscript Choice System (Invitrogen Life Technologies) in the presence of a T7-(dT) 24 DNA oligonucleotide primer. Following synthesis, the cDNA was purified by phenol/chloroform/isoamyl alcohol extraction and ethanol precipitation. The purified cDNA was then transcribed in vitro using the BioArray® High Yield RNA Transcript Labeling Kit (ENZO) in the presence of biotinylated ribonucleotides form biotin labelled cRNA. The labelled cRNA was then purified on an affinity resin (Rneasy, Qiagen), quantified and fragmented. An amount of approximately 10 μg labelled cRNA was hybridized for approximately 16 hours at 45° C. to an expression probe array. The array was then washed and stained twice with streptavidin-phycoerythrin (Molecular Probes) using the GeneChip Fluidics Workstation 400 (Affymetrix). The array was then scanned twice using a confocal laser scanner (GeneArray Scanner®, Agilent) resulting in one scanned image. This resulting “.dat-file” was processed using the MASS program (Affymetrix) into a “.cel-file”. The “.cel file” was then transferred to tan Affymetrix GeneChip Laboratory Information Management System (LIMS) database, which is connected to a UNIX Sun Solaris server through a network filing system that allows for the average intensities for all probes cells (CEL file) to be downloaded into an Oracle database (NPGN). Raw data was converted to expression levels using a “target intensity” of 100. The numerical values displayed are weighted averages of the signal intensities of the probe-pairs comprised in a probe-set for a given transcript sequence (AvgDiff value). The data were checked for quality and loaded in the GeneSpring® software versions 5.0 (Silicon Genetics, Calif., US) for statistical analysis.
Quality control analysis of transcriptome data: The following quality measures were analysed for each sample: Scaling factor, background, percent present calls, AFFX-GAPDH 3′: AFFX-GAPDH 5′-ratio, AFFX-GAPDH 3′ variance, AFFX-Beta-actin 3′: AFFX-Beta-actin 5′-ratio. Biological outliers and tissue contamination were identified using NPGN-database Gene Expression Tools by comparing the average signal intensity per probe set per treatment group to the signal intensity in each sample. Attention was paid to the homogeneity of the data. Average and standard deviation of the background noise level determined the raw data restriction value used in the consequent analysis.
Principal component analysis of transcriptome data: Using SIMCA 10.5 software (Umetrics Inc, Kinnelon N.J., USA), Principal Component Analysis (PCA) was performed on all data generated by the microarrays or on, genes present at least in 2 out of 4 samples in at least 1 group to determine general expression differences/similarities among the samples and identify potential biological or technical outliers. A projection was made on the first two or three principal components for each tissue. Here, the differences between samples represent differences in the level of expression or in the correlation structure of the genes used for the PCA model.
The information was further refined by the use of complementary techniques. In situ hybridization, for example, can indicate precisely which cell type inside an organ is specifically expressing a given gene. This technique based on the detection of RNA is independent of the availability of an antibody. Quantitative PCR has also been used to confirm expression levels of particular genes of interest.
To obtain biomarkers predicting cardiovascular adverse effect of tested compounds/drugs, expression levels of proteins have been analysed in cynomolgus monkey serum and plasma from the present analysis using human Multi-Analyte Profile (MAP) Technology. Human MAP could be used to measure protein levels of more than 80 antigens in monkey serum and plasma (Rules-Based Medicine Inc (RBM®), Austin, Tex. USA).
The following EXAMPLE is presented in order to more fully illustrate the preferred embodiments of the invention. This EXAMPLE should in no way be construed as limiting the scope of the invention, as defined by the appended claims.
Identification of Specific Genomics Signature in Vioxx®-Treated Monkey(s)
Overall genomics data obtained for 16 tissues from all monkey groups showed that the Vioxx®-treated animals exhibit a specific pattern of gene expression. This pattern includes significant increases (ANOVA, p<0.05) in the expression of MHC class I classical and non-classical molecules, MHC class II molecules and their respective receptors such as TcRs and Immunoglobulin-like molecules.
Analysis of genomic data from several cardiovascular tissues by Principle Component Analysis (PCA) on the selected genes composed of MHC molecules identified a biological outlier (Animal no: A60055, circled in the
Further analysis of all genomic data by PLS-DA provided a list of the most discriminate genes between the animal A60055 and the rest of the animals from Vioxx®, Celebrex®, Cox189 (Novartis), diclofenac and vehicle treated groups (TABLE 1,
Interestingly, histopathological evaluation of all tissues showed clear sign of vasculitis in veins only of the Vioxx®-treated animal A60055 (
The role of Vioxx®-induced cox-2 inhibition in the observed genomic and histopathological findings provide a potential link to the increased risks of cardiovascular side effects occurring in patients treated with Vioxx®: The majority of the observed gene expression changes have been known to be directly involved in the pathogenesis of diverse cardiovascular diseases including atherosclerosis, CAD, thrombosis, autoimmune and neurodegenerative diseases. Among the INFγ inducible gene expression changes, the most striking increase was observed for CXCL10 and other chemokines, e.g., CXCL-9, -11 and MCP-1 (CCL-2) (
The strongest increase has been observed in veins (e.g., 20-fold for CXCL10 in pulmonary vein) and adrenal followed by arteries and heart tissues. Much less and irrelevant changes were observed in samples from liver, kidney, GIT, spleen, BM and cartilage. The fact that specific histopathological vascular findings have been observed only in veins and the genomic data show the presence of the specific pattern in all of the CV tissues tested, suggest that the genomic pattern (particularly, some soluble factors e.g., CXCL10 and CCL2) may be considered as early biomarkers for cox-2 inhibition-related CV side-effects or as early biomarkers for minimal (sub-clinical) vasculitis.
Vioxx® exhibits increased angiostatic and focal inflammatory effects predominantly in veins: The in vivo angiogenic effect of PGE2 is well documented experimentally and in particular by the fact that the EP4 receptor signalling has a major role in regulating closure or maintaining potency of the ductus arteriosus in newborns with congenital heart disease. Apart from this expected inhibition of angiogenic effects of PGE2 by coxibs tested in this analysis, Vioxx® strongly induced the expression of CXCL10, and PD-ECGF (both known anti-angiogenic proteins) mainly in iliac and pulmonary veins which suggests that a strong angiostatic effect occurred in the monkey #A60055.
The specific gene expression pattern observed in the monkey treated with Vioxx® strongly suggests the involvement of an endothelial cell tropic CMV-like infection or reactivation: (i) The expression of numbers of genes inducible by INFγ was strongly upregulated in most of the tissues from the Vioxx®-treated monkey. According to the literature, the induction of INFγ pathway is commonly observed during the first phase of CMV infection or reactivation. It has been shown that CMV antigen-stimulated CD4+ T cells from normal healthy CMV-seropositive donors secreted INFγ and TNF alpha, driving chemokines induction in endothelial cells. The strong INFγ pathway induction and histopathological findings of focal vasculitis in animal #A60055 together with the literature data indicate that latent endothelial cell tropic CMV infection might induces specific cellular immune responses, resulting in the induction of chemoatractants, leading to inflammation and endothelial cell injury. Bolovan-Fritts C A et al., J Virol. 78(23):13173-81 (December 2004).
(ii) In the vessels of the monkey A60055, expression of chemokines, mainly CXCL10, MCP-1 and at a lesser degree other chemokines e.g., CXCL9 and -11 were significantly upregulated (e.g., 150 fold increase for MCP-1 in pulmonary vein). It has been shown that atheroma-associated endothelial cells express CXCL10, CXCL9 and CXCL11. Their secretion from IFNγ-stimulated ECs is increased upon IL-1beta, TNF-alpha, and CD40 ligand treatments and decreased in the presence of nitric oxide. Mach F et al., J Clin Invest. 104(8):1041-50 (October 1999). These data suggest the involvement of these cytokines/chemokines in the pathogenesis/progression of inflammatory vascular changes such as arteriosclerosis or vasculitis. More interestingly, mouse CMV infection in an atherosclerosis animal model and in cholesterol-fed C57BL/6J mice significantly increases atherosclerotic lesion area and aortic expression of CXCL10, MCP-1, and other INF-gamma induced proteins. Burnett M S et al., Circulation. 109(7):893-7 (Feb. 24, 2004). Similarly, mouse CMV infection in the brains of immunodeficient mice, stimulates the production of CXCL10 and MCP-1. Cheeran M C et al., J Neurovirol. 10(3):152-62 (June 2004).
In light of these data, our results suggest that an endothelial cell tropic CMV-like reactivation might be the main factor involved in the initiation of the observed vascular changes in this analysis. Interestingly, human CMV encodes four chemokine receptors e.g., US28, which bind many of the human CC-chemokines, including RANTES, MCP-1, CCL3, and CXCL-11. As mentioned above, this class of chemokines contributes to the development of vascular disease such as atherosclerosis, restenosis, and transplant vascular sclerosis. The increased expression of these chemokines genes and/or their respective receptors (TABLE 1) in the monkey treated with Vioxx® raises the question whether they were produced by reactivated CVM virions or by INFγ activated endothelial cells as a result of inflammatory reaction to CMV infection.
Literature data also demonstrate that the induction of COX-2 and/or synthesis of PGE2 are essential for efficient CMV replication in human (Zhu H et al., Proc. Natl. Acad. Sci. USA 99:3932-3937 (2002)) and monkey (Rue C A et al., J Virol. 78(22):12529-36 (November 2004)). Interestingly, the rhesus cytomegalovirus (RhCMV) genome encodes a protein homologue to cellular cox-2 (vCOX-2). Experiments with vCOX-2 deleted RhCMV identified vCOX-2 as a critical determinant for endothelial cell tropism. Rue C A et al., J Virol. 78(22):12529-36 (November 2004).
The cPLA2, a key enzyme in arachidonic acid (AA) release, is the primary form of PLA2 responsible for the generation of PGE2, LTB4 and PAF from AA, in response to inflammatory stimuli. It has been established that cPLA2 exhibits antihypertrophic potential probably via signalling pathway of β2-ARs in heart. Pavoine C & Defer N, Cell Signal. 17(2):141-52 (February 2005). PLA2 signalling pathways has been shown to be involved in human CMV infection in several ways. (i) hCMV infection stimulates arachidonic acid metabolism associated with activation of PLA2 and a cellular cPLA2, (ii) both mRNAs encoding for cPLA2 and COX-2 are increased in infected cells, (iii) blocking the cellular pathway of PLA2 signalling inhibited hCMV infection, and recently (iv) it has been reported that a cPLA2 taken up by virus particles from infected cells plays a role in CMV infection at a post entry step. The inhibition of hCMV-borne cPLA2 had broader consequences on HCMV infection inhibiting the production of key viral antigens IE1, IE2 and pp65. In this monkey analysis, expression of cPLA2 was upregulated in most of the cardiovascular tissues from the Vioxx®-treated monkey only. Since all other monkeys showed no increase of cPLA2 expression, these data also suggest the presence/reactivation of a CMV infection in the endothelial cell of the Vioxx®-treated monkeys.
CMV is known as a strictly opportunistic pathogen, in immunocompetent individuals it is easily controlled yet never eliminated since a robust immune response suppresses persistent viral replication and facilitates a lifelong viral latency. In fact, CMV has several mechanisms to escape diverse host immune responses. CMV encodes for at least four proteins which interfere with classical MHC class I antigen presentation by preventing their cell surface expression, by transporting them to the cytosol, where they are degraded and by competing with TAP for the translocation of antigenic peptides to MHC molecules. However, evasion of MHC I is not perfect, since IFNγ activation by CMV can induce the synthesis of large quantities of MHC I and proteosomes that overwhelm viral inhibitory proteins and “rescue” the CTL response. Two CMV-encoded proteins also interact with non-classical MHC class I such as HLA-E, which leads to suppression of NK responses. CMV encode for the UL18 which has homology to MHC I heavy chain and is expressed on the cell surface. Disruption of UL18 severely restricts viral pathogenesis. CMV also interferes with MHC II presentation, which was strongly upregulated in the Vioxx®-treated monkey (TABLE 1). Classically, INF-gamma is a potent inducer of MHC II expression in many cell types including endothelial cells. However, some studies showed that in CMV-infected cells, IFN-gamma is unable to induce MHC II expression. Recently, MHC class II molecules expressed in EC have been proposed as the entry receptor for CMV. Thus, the protein expression of MHC class II molecules in tissue samples will be tested whether their increased mRNA expression are translated into functional proteins. CMV infection also induces alteration in the expression of important cytokines such as TNF, IGF beta and IL1 and upregulation of the complement control proteins CD46, and CD55. CMV also encodes for a surface Fc-receptor which can bind IgG with high affinity. Interestingly, expression of most of these genes including MHC molecules, several NK cell receptors, complement proteins, Fc receptors was significantly upregulated in the monkey #A60055. These results support the hypothesis that the specific expression pattern is probably induced by a CMV infection in the animal A60055 (TABLE 1).
The expression of Toll like receptor 2 and CD14 was significantly increased in several tissues from the Vioxx®-treated monkey. Recently, it has been shown that CMV activates inflammatory cytokine responses via TLR2/CD14 during the prereplication phase of the viral life cycle. Indeed, interferon and ISGs are robustly induced by CMV particles during entry via activation of IRF3, one of the key transcription factors for INFγ inducible genes. Later during the replication cycle, CMV encodes several chemokines and chemokine receptors that provide potent inflammatory signals. In fact, many of the pathological processes associated with CMV reactivation (including accelerated vascular disease, and graft rejection) appear to be mediated by the release of inflammatory cytokines. Compton T et al., J Virol. 77(8):4588-96 (April 2003). Even though other viruses (measles virus, and RSV), also activate innate responses in a TLR2/CD14-dependent manner, the overall expression pattern suggests that CMV infection/reactivation is probably responsible for the observed vasculitis in the veins of the Vioxx®-treated monkey.
CMV reactivation in the vascular system and use of anti-inflammatory compounds including NSAIDs and specific Cox-2 inhibitors: A number of infectious agents have been associated with atherosclerotic cardiovascular disorders, including CMV, Helicobacter pylori, EBV, HIV, HSV1, HSV2, and hepatitis B and C. Rue C A et al., J Virol. 78(22):12529-36 (November 2004). However, several reports in the literature suggest that the CMV infection/reactivation might be one of the major players in the pathogenesis of chronic inflammatory vascular diseases. For examples, rare cases of CMV vasculitis have been described even in healthy individuals, which may be associated with carotid intimal-medial thickening, or development of extensive mesenteric arterial and venous thrombosis. Other studies suggest that CMV infection or reactivation is involved in post-transplant sub endothelium/intramyocardial inflammation, atherogenesis, restenosis, and inflammatory abdominal aortic aneurysm. Koskinen P K et al., Transpl Infect Dis. 1(2):115-26 (June 1999)). Since ECs are one of the major targets for latent CMV infection, CMV induced lytic or inflammatory reaction in ECs may easily result in adherent thrombi formation in vivo. Thus, infection/reactivation of CMV in endothelial cells may cause vascular injury and promote the development of inflammation, atherosclerotic lesions, and thrombosis. Therefore, the observed vascular findings in this analysis might be the early indicators of a CMV vasculitis.
In line with our current observations on Vioxx® CV effect, Rott D et al., J Am Coll Cardiol. 41(10):1812-9 (May 21, 2003) found that inhibition of Cox-2 aggravated atherosclerosis in the apoE knockout mouse. The authors studied the effect of COX-2 inhibition on infectivity of cytomegalovirus and coincidentally showed increased disease burden in animals treated with the COX-2 inhibitor, including those not infected with the virus. According to the FitzGerald hypothesis (see BACKGROUND OF THE INVENTION), this should reflect selective suppression of PGI2 and an unopposed effect of TXA2, however, the authors suggest an alternative hypothesis indicating that the suppression of anti-inflammatory PGs, such as PGJ2, and its metabolite 15-deoxy-delta12,14-PGJ2 might also result in this type of vascular changes. Rott D et al., J Am Coll Cardiol. 41(10):1812-9 (May 21, 2003). Another hypothesis might be that Cox-2 specific inhibitors but also NSAIDs can also initiate or aggravate atherosclerotic changes by inhibiting the production of PGE2 leading to the reactivation of latent CMV infection. In fact, it has been clearly documented that PGE2 can inhibit replication of viruses including CMV and HIV-1 through activation of cAMP and PKA which are the key enzymes in the negative regulation of immune responses and a potential target for inhibiting autoreactive T cells. Aandahl E M et al., J. Immunol. 169(2):802-8 (Jul. 15, 2002). Other reports support this hypothesis showing that PGE-2 suppresses chemokine production by increasing cAMP trough the EP4 receptor. Takayama K et al., J Biol Chem.277(46):44147-54 (Nov. 15, 2002). It has been shown that PGE2 activated cAMP/PKA inhibits INFγ signalling pathway proteins (JAK-1 and STAT1) and consequently decrease chemokine synthesis such as CXCL10. Kanda N et al., J Invest Dermatol. 119(5):1080-9 (November 2002).
More interestingly, a selective cox-2 inhibitor, NS398, potentiates CXCL10 synthesis upon INFγ stimulation by preventing PGE2 production and PKA activation. Wright K L et al., Br J Pharmacol. 141(7):1091-7 (April 2004). In our analysis, the significant activation of numbers of INFγ inducible genes even in vascular tissues where there was no histopathological abnormalities suggest that Vioxx® has similar potentialization effect on the INFγ pathway activation as described for NS398. Thus, the Vioxx® treatment might lower the threshold for the generation of a chronic vascular inflammation via inhibition of PGE2 and activation of INFγ pathways triggered by reactivation of a latent CMV infection in endothelial cells. It is noteworthy that the CMV seropositivity has been reported in most of the monkey strains and in about 60-70% of healthy individuals. Overall, the data suggest that inhibition of Cox-2 and in particular PGE2 by Vioxx® might results in an uncontrollable/continuous production of soluble factors induced by INFγ pathway activation. The INFγ pathway is commonly induced in case of endothelial/vascular tropic virus infection including some isolates of CMV. As suggested by the presently observed findings, activation of vascular endothelium and attraction of specific blood cells by chemokines (e.g., CXCL10, MCP-1, often activated during a CMV infection) might increase their interaction leading to cardiovascular adverse effects.
The histopathological examination revealed marginal vascular changes consistent with the genomic findings and suggesting that the specific genomic pattern is an early signature of vasculitis and is observed only in the monkey treated with Vioxx® (
Soluble proteins present in serum and plasma of the same monkeys have been measured using a multiplex assay produced by Rules-Based Medicine (RBM®) of Texas. The results were in line with the genomic results showing the increased level of INFγ inducible proteins only in the Vioxx®-treated monkey (
Increased expression of CXCL10 chemokine and INFγ has been confirmed by an ELISA both in serum and plasma from the Vioxx®-treated monkey (
Localisation of several proteins (e.g., PD-ECGF1) at the site of vascular lesion indicates the specificity of changes for a vasculopathy (
Conclusion: Overall genomic data showed that the Vioxx®-treated animals, and in particular the animal #60055 exhibit a specific mRNA expression pattern which strongly suggest the induction of an intravascular procoagulative/prothrombotic state particularly in venous vessels of the Vioxx®-treated animals. The specific genomics pattern includes genes involved in blood and endothelial cell activation, interaction between blood and ECs, strong activation of INFγ pathway, and release of pro-inflammatory cytokines and chemo-attractants. These data together with biochemical and histopathological findings suggest that Vioxx® may exaggerate host immune response during some/specific viral infection(s) with endothelial tropism, suggestively reactivation of a CMV infection.
Our hypothesis is that the inhibition of Cox-2/PGE2 results in decreased level of cAMP and PKA and consequently in an uncontrollable/continuous production of soluble factors via INFγ pathways induced by a CMV infection in endothelial/blood cells. Activation of vascular endothelium and attraction of specific blood cells by chemokines should further increase their interaction leading to prothrombotic events and increasing the risk of cardiovascular adverse events. Indeed, the majority of these changes have been shown to be directly involved in the pathogenesis of diverse cardiovascular diseases including atherosclerosis, CAD, and thrombosis. Preliminary histopathological results confirmed the genomic finding showing that the specific genomics pattern is an early signature of vasculitis and observed only in the animal(s) treated with Vioxx®.
Identification of biomarkers might allow the safe use of cox-2 inhibitory compounds in clinics and selection of cox-2 inhibitory follow-up compounds without cardiovascular toxicity. Indeed, several of the gene increases in the vessels of the Vioxx®-treated animal encode for secreted proteins, e.g., CXCL10, other chemokines, which can be measured in peripheral samples such as blood or urine. If a CMV reactivation (or other endothelium tropic virus infection) is confirmed, a vaccination strategy prior to administration of Cox-2 inhibitory therapies might be an alternative approach for improving the CV therapeutic and safety profile of this class of compounds.
All references cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. In addition, all Affymetrix identification numbers for each probe set corresponding to each gene changes cited herein (TABLE 1) are incorporated herein by reference in their entirety and for all purposes to the same extent as if each such number was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
The present invention is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the invention. Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatus within the scope of the invention, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications and variations are intended to fall within the scope of the appended claims. The present invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.
This application is a divisional application of U.S. application Ser. No.: 12/293,652, filed Nov. 25, 2009. The 12/293,652 application claims priority to International Application Serial No. PCT/IB2006/000533, filed Mar. 10, 2006, which claims priority to U.S. Provisional Application Ser. No.: 60/661,192, filed on Mar. 11, 2005, each of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 20060051873 | FitzGerald | Mar 2006 | A1 |
| 20100221186 | Firat et al. | Sep 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 2 287 608 | Feb 2011 | EP |
| 2 290 363 | Mar 2011 | EP |
| 1 910 825 | Aug 2012 | EP |
| WO 2004112589 | Dec 2004 | WO |
| WO 2006023966 | Mar 2006 | WO |
| WO 2006095259 | Sep 2006 | WO |
| Entry |
|---|
| Fitzgerald, G.A., “Coxibs and Cardiovascular Disease,” N. Engl. J. Med., 351(17), pp. 1709-1711, (2004). |
| Furberg, C.D., et al., “Parecoxib, Valdecoxib, and Cardiovascular Risk,” Circulation, 111(3), p. 249, (2005). |
| Giannitsis, E., “Rationale for testing the cardiovascular risk for patients with Cox-2 inhibitors on the basis of biomarker NT-proBNP,” Clinical Laboratory, vol. 51, No. 1-2, pp. 63-72, (2005). |
| Juni, P., et al., “Risk of cardiovascular events and rofecoxib: cumulative meta-analysis”, The Lancet Limited, vol. 364, No. 9450, pp. 2021-2029, (2004). |
| Kanda, N., et al., “Cyclooxygenase-2 Inhibitor Enhances Whereas Prostaglandin E2 Inhibits the Production of Interferon-Induced Protein of 10 kDa in Epidermoid Carcinoma A431,” Journal of Investigative Dermatology, vol. 119, No. 5, pp. 1080-1089, (2002). |
| Pfister, R., et al., “Natriuretic peptides BNP and NT-pro-BNO: established laboratory markers in clinical practice or just perspectives?” Clinica Chimica Acta, Amsterdam, NL: vol. 349, No. 1-2, pp. 25-38, (2004). |
| Berger et al., “Proteinase 3, the Major Autoantigen of Wegener's Granulomatosis, Enhances IL-8 Production by Endothelial Cells In Vitro1”, J. Am. Soc. Nephrol., 1996, 7(5):694-701. |
| Diavant NT-proBNP, Diagnostic Test of Roche. 1 page. (German Language Translation). |
| Grosser et al., “Biological basis for the cardiovascular consequence of COX-2 inhibition: therapeutic challenges and opportunities”, The Journal of Clinical Investigation, 2006, 116(1):4-15. |
| Guerreiro et al., “Toxicogenomics in Drug Development”, Toxicologic Pathology, 2003, 31:471-479. |
| Guher et al., “Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases”, Journal of Neuroimmunology, 2003, 145(1-2):127-134, (Abstract). |
| International Search Report for International Application PCT/IB2006/000533, provided by the International Searching Authority, mailed Oct. 13, 2006. |
| Kano et al., “Cellular and Molecular Dynamics in Exercise-Induced Urticarial Vasculitis Lesions”, Archives of Dermatology, 1998, 134:62-67, Date of Access: Jun. 1, 2016, http://archderm.jamanetwork.com/article.aspx?articleid=188563. |
| Kearney et al., “Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials”, BMJ Online First, 2006. |
| Palop-Larrea et al., “Leukocytoclastic vasculitis related to rofecoxib”, Annals of Pharmacotherapy, 2003, 37:1731-1732. |
| Sari et al., Interferon alpha-Inducible Protein 27 (IF127) is Upregulated in Psoriatic Skin and Certain Epithelial Cancers, J. Invest. Dermatol., 2004, 122(3):717-721. |
| Schneider et al., “Fatal allergic vasculitis associated with celecoxib”, The Lancet, 2002, 359(9309):852-853, (Abstract). |
| Terai et al, “Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment”, Journal of Leukocyte Biology, 1999, 65:566-572. |
| United States Food and Drug Administration, “Drugs: Information for Healthcare Professional Celecoxib”, Apr. 7, 2005. 2 pages. |
| Wright et al., “Differential regulation of prostaglandin E biosynthesis by interferon-γ in colonic epithelial cells”, British Journal of Pharmacology, 2004, 141(7):1091-1097. |
| Number | Date | Country | |
|---|---|---|---|
| 20150152501 A1 | Jun 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60661192 | Mar 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12293652 | US | |
| Child | 14543789 | US |
